Skip to main content

Advertisement

SpringerLink
Log in

Sensitization of MDA-MBA231 breast cancer cell to docetaxel by myricetin loaded into biocompatible lipid nanoparticles via sub-G1 cell cycle arrest mechanism

  • Original Article
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

The harmful dose-dependent side effects of chemotherapy drugs have caused the discovery of novel perspective to evaluate chemotherapy protocols. In this study, the potential application of Compritol was investigated as a major scaffold into nanostructured lipid careers to highlight myricetin efficiency in treatment of breast cancer cells along with codelivery of docetaxel (DXT). Characterization of myricetin-loaded NLCs was carried out by measuring the particle size and zeta potential, using the scanning electron microscopy. MTT, DAPI staining, flow cytometric, and RT-PCR (real-time) assays were used to recognize novel formulation behavior on cell cytotoxicity as well as recognizing molecular mechanism of formulation concerning apoptosis phenomenon. Myricetin-loaded NLCs reduced the cell viability from 50 ± 2.3 to 40 ± 1.3% (p < 0.05). Percentage of apoptosis improved with combination treatment of myricetin-loaded NLCs and DXT in the MDA-MBA231 breast cancer cells. Expression of antiapoptotic genes (survivin, Cyclin B1, and Mcl1) indicated a significant reduction in factor along with increment in proapoptotic factor Bax and Bid mRNA rates. Overall, our results represented that the NLC delivery system could be a promising strategy to enhance the effect of anticancer agents such as DXT on breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  • Alshaker H, Pchejetski D (2018) PO-432 New combined nanoparticle therapy inhibits metastatic breast tumour growth with superior efficacy and lower side effect profile to docetaxel. BMJ Publishing Group Limited, pp A191–A192

  • Athawale RB, Jain DS, Singh KK, Gude RP (2014) Etoposide loaded solid lipid nanoparticles for curtailing B16F10 melanoma colonization in lung. Biomed Pharmacother 68:231–240

    Article  CAS  Google Scholar 

  • Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC (2014) Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 66:2–25

    Article  CAS  Google Scholar 

  • Bhattarai N, Mathis JM, Chen M, Perez RL, Siraj N, Magut PK, McDonough K, Sahasrabudhe G, Warner IM (2018) Endocytic selective toxicity of rhodamine 6G nanoGUMBOS in breast cancer cells. Mol Pharm 15:3837–3845

    Article  CAS  Google Scholar 

  • Devi KP, Rajavel T, Habtemariam S, Nabavi SF, Nabavi SM (2015) Molecular mechanisms underlying anticancer effects of myricetin. Life Sci 142:19–25

    Article  CAS  Google Scholar 

  • Feng J, Chen X, Wang Y, Du Y, Sun Q, Zang W, Zhao G (2015) Myricetin inhibits proliferation and induces apoptosis and cell cycle arrest in gastric cancer cells. Mol Cell Biochem 408:163–170

    Article  CAS  Google Scholar 

  • Fragni M, Bonini S, Bettinsoli P, Bodei S, Generali D, Bottini A, Spano P, Memo M, Sigala S (2016) The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines. Naunyn Schmiedeberg's Arch Pharmacol 389:529–538

    Article  CAS  Google Scholar 

  • Gadgil P, Shah J, Chow D-L (2018) Enhanced brain delivery with lower hepatic exposure of lazaroid loaded nanostructured lipid carriers developed using a design of experiment approach. Int J Pharm 544:265–277

    Article  CAS  Google Scholar 

  • Guo RX, Fu X, Chen J, Zhou L, Chen G (2016) Preparation and characterization of microemulsions of myricetin for improving its antiproliferative and antioxidative activities and oral bioavailability. J Agric Food Chem 64:6286–6294

    Article  CAS  Google Scholar 

  • Haddad A, Venkateswaran V, Viswanathan L, Teahan S, Fleshner N, Klotz L (2006) Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate Cancer Prostatic Dis 9:68–76

    Article  CAS  Google Scholar 

  • Hajipour H, Hamishehkar H, Nazari Soltan Ahmad S, Barghi S, Maroufi NF, Taheri RA (2018a) Improved anticancer effects of epigallocatechin gallate using RGD-containing nanostructured lipid carriers. Artif Cells Nanomed Biotechnol 46:283–292

    Article  CAS  Google Scholar 

  • Hajipour H, Hamishehkar H, Rahmati-Yamchi M, Shanehbandi D, Ahmad SNS, Hasani A (2018b) Enhanced anti-cancer capability of ellagic acid using solid lipid nanoparticles (SLNs). IJCM 11

  • Hatakeyama H, Akita H, Harashima H (2011) A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev 63:152–160

    Article  CAS  Google Scholar 

  • Huang H, Chen AY, Ye X, Li B, Rojanasakul Y, Rankin GO, Chen YC (2015) Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway. Int J Oncol 47:1494–1502

    Article  CAS  Google Scholar 

  • Khazir J, Riley DL, Pilcher LA, De-Maayer P, Mir BA (2014) Anticancer agents from diverse natural sources. Nat Prod Commun 9: 1934578X1400901130

    Article  Google Scholar 

  • Ko C-H, Shen S-C, Lee TJ, Chen Y-C (2005) Myricetin inhibits matrix metalloproteinase 2 protein expression and enzyme activity in colorectal carcinoma cells. Mol Cancer Ther 4:281–290

    CAS  PubMed  Google Scholar 

  • Lee DH, Lee CS (2016) Flavonoid myricetin inhibits TNF-α-stimulated production of inflammatory mediators by suppressing the Akt, mTOR and NF-κB pathways in human keratinocytes. Eur J Pharmacol 784:164–172

    Article  CAS  Google Scholar 

  • López-Lázaro M, Willmore E, Austin CA (2010) The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells. Mutat Res Genet Toxicol Environ Mutagen 696:41–47

    Article  Google Scholar 

  • Lu J, Papp LV, Fang J, Rodriguez-Nieto S, Zhivotovsky B, Holmgren A (2006) Inhibition of mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res 66:4410–4418

    Article  CAS  Google Scholar 

  • Mahmoudi S, Ghorbani M, Sabzichi M, Ramezani F, Hamishehkar H, Samadi N (2019) Targeted hyaluronic acid-based lipid nanoparticle for apigenin delivery to induce Nrf2-dependent apoptosis in lung cancer cells. J Drug Delivery Sci Technol 49:268–276

    Article  CAS  Google Scholar 

  • Martins S, Sarmento B, Ferreira DC, Souto EB (2007) Lipid-based colloidal carriers for peptide and protein delivery–liposomes versus lipid nanoparticles. Int J Nanomedicine 2:595

    CAS  PubMed  PubMed Central  Google Scholar 

  • Mennini N, Cirri M, Maestrelli F, Mura P (2016) Comparison of liposomal and NLC (nanostructured lipid carrier) formulations for improving the transdermal delivery of oxaprozin: effect of cyclodextrin complexation. Int J Pharm 515:684–691

    Article  CAS  Google Scholar 

  • Minaei A, Sabzichi M, Ramezani F, Hamishehkar H, Samadi N (2016) Co-delivery with nano-quercetin enhances doxorubicin-mediated cytotoxicity against MCF-7 cells. Mol Biol Rep 43:99–105

    Article  CAS  Google Scholar 

  • Mohammadian J, Sabzichi M, Molavi O, Shanehbandi D, Samadi N (2016) Combined treatment with stattic and docetaxel alters the Bax/Bcl-2 gene expression ratio in human prostate cancer cells. APJCP 17:5031

    PubMed  Google Scholar 

  • Oh E-T, Kim CW, Kim SJ, Lee J-S, Hong S-S, Park HJ (2016) Docetaxel induced-JNK2/PHD1 signaling pathway increases degradation of HIF-1α and causes cancer cell death under hypoxia. Sci Rep 6:27382

    Article  CAS  Google Scholar 

  • Phillips P, Sangwan V, Borja-Cacho D, Dudeja V, Vickers S, Saluja A (2011) Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of the phosphatidylinositol 3-kinase (PI3K) signaling pathway. Cancer Lett 308:181–188

    Article  CAS  Google Scholar 

  • Raeisi S, Chavoshi H, Mohammadi M, Ghorbani M, Sabzichi M, Ramezani F (2019) Naringenin-loaded nano-structured lipid carrier fortifies oxaliplatin-dependent apoptosis in HT-29 cell line. Process Biochem 83:168–175

    Article  CAS  Google Scholar 

  • Sabzichi M, Mohammadian J, Ghorbani M, Saghaei S, Chavoshi H, Ramezani F, Hamishehkar H (2017a) Fabrication of all-trans-retinoic acid-loaded biocompatible precirol: a strategy for escaping dose-dependent side effects of doxorubicin. Colloids Surf B: Biointerfaces 159:620–628

    Article  CAS  Google Scholar 

  • Sabzichi M, Mohammadian J, Mohammadi M, Jahanfar F, Movassagh Pour AA, Hamishehkar H, Ostad-Rahimi A (2017b) Vitamin D-loaded nanostructured lipid carrier (NLC): a new strategy for enhancing efficacy of doxorubicin in breast cancer treatment. Nutr Cancer 69:840–848

    Article  CAS  Google Scholar 

  • Shih Y-W, Wu P-F, Lee Y-C, Shi M-D, Chiang T-A (2009) Myricetin suppresses invasion and migration of human lung adenocarcinoma A549 cells: possible mediation by blocking the ERK signaling pathway. J Agric Food Chem 57:3490–3499

    Article  CAS  Google Scholar 

  • Üner M, Wissing S, Yener G, Müller R (2004) Influence of surfactants on the physical stability of solid lipid nanoparticle (SLN) formulations. Pharmazie 59:331–332

    PubMed  Google Scholar 

  • Wang S, Ye T, Zhang X, Yang R, Yi X (2013) Myricetin microemulsion for oral drug delivery: formulation optimization, in situ intestinal absorption and in-vivo evaluation. Asian J Pharm Sci 8:18–27

    Google Scholar 

  • Zhang X-H, Zou Z-Q, Xu C-W, Shen Y-Z, Li D (2011) Myricetin induces G2/M phase arrest in HepG2 cells by inhibiting the activity of the cyclin B/Cdc2 complex. Mol Med Rep 4:273–277

    CAS  PubMed  Google Scholar 

Download references

Funding

This project was financially supported by a grant from the Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran (grant no. 58991).

Author information

Authors and Affiliations

  1. Stem Cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran

    Nazila Fathi Maroufi & Maryam Akbarzadeh

  2. Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

    Nazila Fathi Maroufi, Hosein Ajami Khiavy & Roya Bazzaz

  3. Department of Clinical Biochemistry and Laboratory Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

    Nazila Fathi Maroufi

  4. Department of Medical Laboratory Sciences, Faculty of Medicine, Islamic Azad University (IAU), Sari, Iran

    Vahid Vahedian

  5. Department of Biology, Faculty of Basic Sciences, Yazd University, Yazd, Iran

    Seyed Ali Miresmaeili Mazrakhondi

  6. Lung Diseases and Allergy Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran

    Wesam Kooti

  7. Department of Molecular Medicine, Faculty of Advanced Medical Science, Tabriz University of Medical Sciences, Tabriz, Iran

    Fatemeh Ramezani

  8. Department of Genetic and Bioengineering, Faculty of Engineering and Architecture, Yeditepe University, 34755, Istanbul, Turkey

    Seyed Mohammadbagher Pirouzpanah

  9. Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    Marjan Ghorbani

  10. Department of Reproductive Biology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran

    Hamed Hajipour

  11. Cancer Gene Therapy Research Center, Zanjan University of Medical Science, Zanjan, Iran

    Saeed Ghanbarzadeh

  12. Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada

    Mehdi Sabzichi

Authors
  1. Nazila Fathi Maroufi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vahid Vahedian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seyed Ali Miresmaeili Mazrakhondi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wesam Kooti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hosein Ajami Khiavy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Roya Bazzaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fatemeh Ramezani
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Seyed Mohammadbagher Pirouzpanah
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Marjan Ghorbani
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Maryam Akbarzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hamed Hajipour
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Saeed Ghanbarzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Mehdi Sabzichi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

N.F.M. and V.V. had the main contribution in conception and design and are involved in the performance of experiments, data analysis and interpretation, and manuscript writing; S.A.M.M. and H.K. are involved in the data analysis and manuscript writing; K.W., R.B., F.R., and M.G. are involved in some molecular experiments; M.A. and H.H. are involved in data analysis and interpretation. S.G. and M.S. are involved in the performance of all experiments.

Corresponding authors

Correspondence to Saeed Ghanbarzadeh or Mehdi Sabzichi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maroufi, N.F., Vahedian, V., Mazrakhondi, S.A.M. et al. Sensitization of MDA-MBA231 breast cancer cell to docetaxel by myricetin loaded into biocompatible lipid nanoparticles via sub-G1 cell cycle arrest mechanism. Naunyn-Schmiedeberg's Arch Pharmacol 393, 1–11 (2020). https://doi.org/10.1007/s00210-019-01692-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-019-01692-5

Keywords

Search

Navigation